BPGbio Announces Phase 2 BPM31510 Glioblastoma Trial-in-Progress Update at Society for Neuro-Oncology Annual Meeting
"The information gathered from preclinical and clinical research has offered valuable insights into treatment for GBM, and we eagerly anticipate continuing to advance our discoveries with neoadjuvant BPM31510."
- "The information gathered from preclinical and clinical research has offered valuable insights into treatment for GBM, and we eagerly anticipate continuing to advance our discoveries with neoadjuvant BPM31510."
- The ongoing first-line Phase 2b trial ( NCT04752813 ) follows a successful 104-patient Phase 1a/b clinical trial, which demonstrated both the safety and efficacy of BPM31510.
- The Phase 1a/b data , which were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in 2019, helped the BPGbio team plan for a Phase 1b trial in advanced GBM patients, where BPM31510 was well tolerated.
- BPGbio is planning to expand the Phase 2b trial to new clinical sites in the United States and the United Kingdom.